Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer
- PMID: 18311903
- PMCID: PMC3640352
- DOI: 10.1021/pr700804c
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer
Abstract
There is strong preclinical evidence that cancer, including breast cancer, undergoes immune surveillance. This continual monitoring, by both the innate and the adaptive immune systems, recognizes changes in protein expression, mutation, folding, glycosylation, and degradation. Local immune responses to tumor antigens are amplified in draining lymph nodes, and then enter the systemic circulation. The antibody response to tumor antigens, such as p53 protein, are robust, stable, and easily detected in serum; may exist in greater concentrations than their cognate antigens; and are potential highly specific biomarkers for cancer. However, antibodies have limited sensitivities as single analytes, and differences in protein purification and assay characteristics have limited their clinical application. For example, p53 autoantibodies in the sera are highly specific for cancer patients, but are only detected in the sera of 10-20% of patients with breast cancer. Detection of p53 autoantibodies is dependent on tumor burden, p53 mutation, rapidly decreases with effective therapy, but is relatively independent of breast cancer subtype. Although antibodies to hundreds of other tumor antigens have been identified in the sera of breast cancer patients, very little is known about the specificity and clinical impact of the antibody immune repertoire to breast cancer. Recent advances in proteomic technologies have the potential for rapid identification of immune response signatures for breast cancer diagnosis and monitoring. We have adapted programmable protein microarrays for the specific detection of autoantibodies in breast cancer. Here, we present the first demonstration of the application of programmable protein microarray ELISAs for the rapid identification of breast cancer autoantibodies.
Figures





Similar articles
-
Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.Proteomics Clin Appl. 2016 Jul;10(7):720-31. doi: 10.1002/prca.201500096. Epub 2016 May 17. Proteomics Clin Appl. 2016. PMID: 27121307 Free PMC article.
-
Detection of autoantibodies to survivin and livin in sera from patients with breast cancer.Clin Chim Acta. 2005 Dec;362(1-2):125-30. doi: 10.1016/j.cccn.2005.06.009. Epub 2005 Jul 18. Clin Chim Acta. 2005. PMID: 16026775
-
Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays.J Immunol Methods. 2009 Oct 31;350(1-2):171-82. doi: 10.1016/j.jim.2009.08.013. Epub 2009 Sep 2. J Immunol Methods. 2009. PMID: 19732778 Free PMC article.
-
Autoantibodies in cancer: prognostic biomarkers and immune activation.Expert Rev Proteomics. 2011 Oct;8(5):577-89. doi: 10.1586/epr.11.48. Expert Rev Proteomics. 2011. PMID: 21999829 Review.
-
Autoantibody profiles as biomarkers of breast cancer.Cancer Biomark. 2010;6(5-6):247-56. doi: 10.3233/CBM-2009-0139. Cancer Biomark. 2010. PMID: 20938085 Review.
Cited by
-
Simple screening method for autoantigen proteins using the N-terminal biotinylated protein library produced by wheat cell-free synthesis.J Proteome Res. 2010 Aug 6;9(8):4264-73. doi: 10.1021/pr9010553. J Proteome Res. 2010. PMID: 20575507 Free PMC article.
-
Immunoproteomic Profiling of Antiviral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays.Diabetes. 2016 Jan;65(1):285-96. doi: 10.2337/db15-0179. Epub 2015 Oct 8. Diabetes. 2016. PMID: 26450993 Free PMC article.
-
Identification of Antibody Targets for Tuberculosis Serology using High-Density Nucleic Acid Programmable Protein Arrays.Mol Cell Proteomics. 2017 Apr;16(4 suppl 1):S277-S289. doi: 10.1074/mcp.M116.065953. Epub 2017 Feb 21. Mol Cell Proteomics. 2017. PMID: 28223349 Free PMC article.
-
Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.J Proteome Res. 2011 Jan 7;10(1):85-96. doi: 10.1021/pr100686b. Epub 2010 Nov 23. J Proteome Res. 2011. PMID: 20977275 Free PMC article.
-
Cancer prognostics by direct detection of p53-antibodies on gold surfaces by impedance measurements.Small. 2012 Jul 9;8(13):2106-15. doi: 10.1002/smll.201102724. Epub 2012 Apr 17. Small. 2012. PMID: 22511467 Free PMC article.
References
-
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. - PubMed
-
- Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC., Jr American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312. - PubMed
-
- Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259–73. - PubMed
-
- Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18(5):868–73. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous